Natco Pharma will be launching about 10 new products in the domestic branded formulations segment in the present financial year and is targeting over 20 per cent growth year-on-year.

“The focus will be on rich molecules with high barriers to entry,’’ the Hyderabad-based company said in an investor presentation on Monday.

The new cardiology and diabetology division launched in early 2017 is also expected to gain traction. Last month, Natco launched Argatroban injection for the first time in India for the treatment with thrombosis syndrome.

In the domestic oncology segment, the company claims to be Number 1 now after entering the market with Imatinib in 2003. It has 28 products now and six brands occupy Number 1 position in the market.

The compounded annual growth rate of revenue in the oncology division since 2014 has been at 27.1 per cent. It reached ₹322.4 crore in FY2017 against ₹157.2 crore in 2014.

Complex generics

In the complex generics portfolio, the Hyderabad-based Natco is also expecting “near term’’ approval for some key molecules such as Copaxone, Lanthanum Carbonate and Bosentan.

Generic renal disease drug

It has received final nod from the US Food and Drug Administration (FDA) for Abbreviated New Drug Application (ANDA) for lanthanum carbonate chewable tablets. The product, as the first generic, will be launched shortly in the US market.

The drug is the generic equivalent of Shire Development LLC’s Fosrenol and is indicated to reduce serum phosphate in patients with end stage renal disease.

Related Topics
comment COMMENT NOW